CSAAI 2024 Educational Meeting, A Midsummer Night’s Wheeze

Sonoma, CA US
June 28, 2024 to June 30, 2024

It is an exciting time in the field of allergy and immunology.  This CME/CEU program is designed to allow attendees to continue exploring the field.  Covered topics include food allergy therapies, immunodefiency, CVID and ILD, asthma management through pregnancy, social determinants of health and disparities in children, among others. 

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and  California Society of Allergy, Asthma & Immunology (CSAAI). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 10.50 contact hours.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

At the conclusion of this Activity learners should be able to…
•    Review clinical data on the efficacy and safety of allergen immunotherapy
•    Determine the optimal regimen and duration of allergen Immunotherapy 
•    Evaluate and select evolving therapeutic strategies
•    Review mechanisms, current biologics and effects
•    Evaluate current clinical data indicating suggesting possible remittive effects of biologics in asthma
•    Select appropriate patients for oral food challenge
•    Identify safety precautions necessary for conducting oral food challenge
•    Describe recent advances in OIT, SLIT and EPIT
•    Identify advantages and disadvantages of all methods of treatment
•    Be prepared to discuss advances, expectations and limitations with your food allergic patients
•    Describe the cardinal manifestations of immune deficiencies and how to distinguish these immune defects.  
•    Determine the infectious and non-infectious complications of immune deficiencies and the laboratory measures and genetic studies that can dissect these issues. 
•    Assess the effects of immune globulin therapies on immunologic systems
•    Review the pathophysiologic mechanisms underlying innate immunity defects
•    Make the earliest possible diagnosis for patients with CVID based on clinical, genetic and other features, and use a patient-centered approach that incorporates each patient’s goals and values to select appropriate treatment.
•    Describe an approach to clinically evaluate CVID including both clinical, genetic, and other features.  
•    Use clinical, laboratory, and genetic features to formulate a treatment regimen for CVID that addresses both immune deficiency and immune dysregulation features of the disease.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 10.50 AMA PRA Category 1 Credit™
  • 10.50 Attendance
  • 10.50 CBRN
Course opens: 
06/28/2024
Course expires: 
06/30/2025
Event starts: 
06/28/2024 - 1:00pm CDT
Event ends: 
06/30/2024 - 11:45am CDT
Add to calendar: 
Rating: 
0

CSAAI 31st Annual Educational Meeting: A Midsummer Night’s Wheeze
June 28-30, 2024
Fairmont Sonoma Mission Inn, Sonoma, CA

FRIDAY, JUNE 28

1:00 pm Registration and Exhibits

2:50 pm Welcome and Overview, Barbara Ariue, MD, President CSAAI

Friday Practice Management Symposium featuring Dr. Katherine Anagnostou & Dr. Priya Bansal: 
brought to you by California Society of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology

3:00 pm Shared Decision-Making: Collaboration between the Allergist and Patient, Katherine Anagnostou, MD, MSc, PhD, FACAA

4:00 pm Top Allergy Papers

An Observational Study of Environmental Allergy Skin Prick Testing versus Serum Antigen-Specific Immunoglobulin E Testing on Asthma Control and Maintenance 
Jessica Sworzyn, MD, MS

Using Mepolizumab to Treat a Childhood Case of Idiopathic Hypereosinophilic Syndrome
Erika Cherk, MD

Town Hall Meeting
5:00 pm  Remote Patient Monitoring and Using Tech in Your Allergy/Immunology Practice, Priya Bansal, MD, FACAA

5:45 pm-6:00 pm Panel Q&A

6:00 pm  Reception

SATURDAY, JUNE 29

7:00 am Exhibits

8:00 am Overview, Sonal Patel, MD, Program Director

8:10am Can Asthma be Prevented?  Strategies Tried and Logical Next Steps, Wanda Phipatanakul, MD, MS

8:50 am Food Allergy Therapies:  The Old, The New and Everything In Between, Katherine Anagnostou, MD, MSc, PhD, FACAA

9:30 am ABC’s of OIT, Sakina Bajowala, MD, 

10:10 am Panel Discussion/Q&A

10:30 am Break and Exhibits

10:50 am Asthma and Allergic Disease Across the Lifespan of Women, Jennifer Namazy, MD

11:30 am Impact of Particulate Air Pollution on Community Health, Sakina Bajowala, MD, FAAAAI

12:10 pm Immunodeficiency, Charlotte Cunningham-Rundles, MD, PhD

12:50 pm Panel Discussion/Q&A

1:05 pm Adjourn

SUNDAY, JUNE 30

7:00 am Break & Exhibits

8:00 am Overview, Raffi Tachdjian, MD, MPH, Executive Director

8:10 am Biologic Therapies in an A/I Practice, Priya Bansal, MD, FACAA

8:50 am CVID and ILD:  from Diagnosis to Therapy, Charlotte Cunningham-Rundles, MD, PhD

9:30 am Panel Discussion/Q&A

9:45 am Break & Exhibits

10:00 am Social Determinants of Health & Disparities in Children: Where are we Now and into the Future?, Wanda Phipatanakul, MD, MS

10:40 am Improving Asthma Management Through Pregnancy, Jennifer Namazy, MD

11:20 am Panel Discussion/Q&A

11:30 am Closing Remarks, Barbara Ariue, MD, President CSAAI

11:45 am Adjourn

Fairmont Sonoma Mission Inn
100 Boyes Blvd.
Sonoma, CA 95476
United States

All relevant financial relationships with ineligible companies have been mitigated.

Aikaterini Anagnostou, MD, PhD: Speaker
Advisor – Bryn, Genentech, Norvartis; Consultant – Ready, Set, Food; Researcher – Norvartis, Speaker – Genentech

Sakina S. Bajowala, MD, FAAAAI: Speaker
Advisor – ARS Pharma, Novartis; Ownership interest – WisePrince LLC

Priya Bansal, MD, FACAAI: Speaker
Advisor – AstraZeneca, GSK, KalVista, Teva; Advisory Board – CSL Behring, Takeda ; Consultant – AstraZeneca, Blueair, GSK, Sanofi/Regeneron; Speaker – AstraZeneca, CSL Behring, GSK, Sanofi/Regeneron, Takeda, Teva

Charlotte Cunningham-Rundles, MD, PhD: Speaker
Advisor – Grifols, Pharming

Jennifer Namazy, MD: Speaker
Independent contractor – GSK 

Wanda Phipatanakul, MD, MS: Speaker
Consultant – AstraZeneca, Genentech, GSK, Novartis, Regeneron, Sanofi; Speaker – AstraZeneca, Genentech, GSK, Novartis, Regeneron, Sanofi 

Barbara Ariue, MD: Planner, Moderator
Speaker – Pharming

Sonal R. Patel, MD: Planner, Moderator
Speaker – Regeneron, Sanofi

Raffi Tachdjian, MD, MPH: Planner, Moderator
Advisor – Astria, BioCryst, CSL Behring, Ionis, KalVista, Pharming, Pharvaris, Takeda; Independent contractor – Allakos, Astria, BioCryst, CSL Behring, Ionis, KalVista, Pharming, Pharvaris, Takeda; Speaker – AstraZeneca, BioCryst, CSL Behring, GSK, Pharming, Regeneron/Sanofi, Takeda

The following have no relevant financial relationships with ineligible companies to disclose:

Sheila M. Bonilla, MD: Planner
Erika Cherk, MD: Speaker
LanAnh Do, MD: Planner
Myngoc Nguyen, MD: Planner
Javed Sheikh, MD: Planner
Jessica Sworzyn: Speaker
Suzanne Teuber, MD: Planner
Karol Anderson: Planner
 

Available Credit

  • 10.50 AMA PRA Category 1 Credit™
  • 10.50 Attendance
  • 10.50 CBRN
Please login or create an account to take this course.